Jitsubo
Minoh, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese biotech developing efficient peptide manufacturing technology for metabolic disease therapeutics through its proprietary Molecular Hiving™ platform.
Metabolic Disorders
Technology Platform
Molecular Hiving™ is a tag-assisted liquid-phase peptide synthesis technology that uses hydrophobic tags to enable homogeneous reactions, simplified scale-up, and reduced solvent consumption compared to traditional solid-phase methods.
Opportunities
Growing demand for peptide therapeutics in metabolic diseases like diabetes and obesity, particularly GLP-1 analogs, creates significant manufacturing opportunities.
Expansion into additional therapeutic areas and geographic markets could drive further growth.
Risk Factors
Dependence on a single major partnership with Novo Nordisk creates concentration risk.
Technology scale-up challenges and competition from established peptide CDMOs with greater resources and track records.
Competitive Landscape
Competes with established peptide CDMOs like Bachem, PolyPeptide, and CordenPharma. Differentiation through proprietary Molecular Hiving™ technology claiming advantages in scalability, cost, and environmental footprint compared to traditional solid-phase peptide synthesis.